Literature DB >> 19333872

Novel approaches on epigenetics.

Roberto Papait1, Elena Monti, Ian M Bonapace.   

Abstract

Epigenetic changes occurring during the development of organisms can be altered by the presence of synthetic substances in the environment, resulting in developmental reprogramming and disease. The occurrence of such changes supports the theory that diseases might be cured by altering the epigenetic regulation of gene expression, either directly by modifying the control of the misregulated genes that cause a disease, or indirectly by 'reprogramming' cells toward a 'normal' gene expression pattern. Launched drugs that inhibit DNA methyltransferases or histone deacetylases and lead to epigenetic changes are currently in use for the treatment of cancer. In addition, recent advancements in the understanding of epigenetic mechanisms involved in tumor development and neurodisorders have enabled new approaches for the development of specific epigenetic therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19333872

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN: 1367-6733


  10 in total

Review 1.  Chemical and biochemical approaches in the study of histone methylation and demethylation.

Authors:  Keqin Kathy Li; Cheng Luo; Dongxia Wang; Hualiang Jiang; Y George Zheng
Journal:  Med Res Rev       Date:  2012-07       Impact factor: 12.944

Review 2.  Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.

Authors:  Paul A Marks
Journal:  Biochim Biophys Acta       Date:  2010-06-08

3.  Histone deacetylase activators: N-acetylthioureas serve as highly potent and isozyme selective activators for human histone deacetylase-8 on a fluorescent substrate.

Authors:  Raushan K Singh; Tanmay Mandal; Narayanaganesh Balsubramanian; Tajae Viaene; Travis Leedahl; Nitesh Sule; Gregory Cook; D K Srivastava
Journal:  Bioorg Med Chem Lett       Date:  2011-08-04       Impact factor: 2.823

4.  Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography.

Authors:  Jacob M Hooker; Sung Won Kim; David Alexoff; Youwen Xu; Colleen Shea; Alicia Reid; Nora Volkow; Joanna S Fowler
Journal:  ACS Chem Neurosci       Date:  2010       Impact factor: 4.418

Review 5.  Genetics of psychiatric disorders methods: molecular approaches.

Authors:  Dimitrios Avramopoulos
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 6.  The multi-functionality of UHRF1: epigenome maintenance and preservation of genome integrity.

Authors:  Monica Mancini; Elena Magnani; Filippo Macchi; Ian Marc Bonapace
Journal:  Nucleic Acids Res       Date:  2021-06-21       Impact factor: 16.971

7.  Lestaurtinib inhibits histone phosphorylation and androgen-dependent gene expression in prostate cancer cells.

Authors:  Jens Köhler; German Erlenkamp; Adrien Eberlin; Tobias Rumpf; Inna Slynko; Eric Metzger; Roland Schüle; Wolfgang Sippl; Manfred Jung
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

Review 8.  Preventive and therapeutic strategies for bovine leukemia virus: lessons for HTLV.

Authors:  Sabrina M Rodríguez; Arnaud Florins; Nicolas Gillet; Alix de Brogniez; María Teresa Sánchez-Alcaraz; Mathieu Boxus; Fanny Boulanger; Gerónimo Gutiérrez; Karina Trono; Irene Alvarez; Lucas Vagnoni; Luc Willems
Journal:  Viruses       Date:  2011-07-19       Impact factor: 5.048

9.  NBM-HD-1: A Novel Histone Deacetylase Inhibitor with Anticancer Activity.

Authors:  Wei-Jan Huang; Yu-Chih Liang; Shuang-En Chuang; Li-Ling Chi; Chi-Yun Lee; Chia-Wei Lin; Ai-Ling Chen; Jing-Shi Huang; Chun-Jung Chiu; Cheng-Feng Lee; Chung-Yang Huang; Chia-Nan Chen
Journal:  Evid Based Complement Alternat Med       Date:  2011-10-20       Impact factor: 2.629

10.  Zebularine regulates early stages of mESC differentiation: effect on cardiac commitment.

Authors:  A Horrillo; D Pezzolla; M F Fraga; Y Aguilera; C Salguero-Aranda; J R Tejedo; F Martin; F J Bedoya; B Soria; A Hmadcha
Journal:  Cell Death Dis       Date:  2013-04-04       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.